Provided by Tiger Trade Technology Pte. Ltd.

Monte Rosa Therapeutics

9.92
-0.2500-2.46%
Volume:39.04K
Turnover:389.20K
Market Cap:846.31M
PE:-5.68
High:10.04
Open:10.04
Low:9.87
Close:10.17
52wk High:25.77
52wk Low:7.44
Shares:85.31M
Float Shares:54.48M
Volume Ratio:0.48
T/O Rate:0.07%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.7450
EPS(LYR):-0.4650
ROE:-42.66%
ROA:-21.63%
PB:1.74
PE(LYR):-21.33

Loading ...

Monte Rosa Therapeutics (GLUE) Joins Russell Growth Indexes, Is The Upside Already Priced In?

Simply Wall St.
·
Jun 30

Monte Rosa Therapeutics CSO Sharon Townson Disposes of 3,000 Common Shares for $60,000

Reuters
·
Jun 26

Wells Fargo Keeps Their Buy Rating on Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
Jun 24

Monte Rosa CSO Sharon Townson disposes of 3,000 common shares worth $57,000

Reuters
·
Jun 19

Monte Rosa Therapeutics held annual shareholder meeting

Reuters
·
Jun 12

Monte Rosa CEO Markus Warmuth sells USD 106,197 of common shares

Reuters
·
Jun 03

Monte Rosa grants inducement awards to new hires, including options for 20,050 shares at USD 19.67

Reuters
·
Jun 03

Monte Rosa Therapeutics CSO Sharon Townson disposes of common shares worth $119,220

Reuters
·
Jun 02

Monte Rosa posts corporate deck spotlighting molecular glue degrader pipeline for immunology, inflammation and cancer targets

Reuters
·
Jun 01

Monte Rosa COO Jennifer Champoux disposes of 2,175 shares for $43,500

Reuters
·
May 29

Monte Rosa COO Jennifer Champoux sells 2,176 common shares worth $41,344

Reuters
·
May 27

Insider Shake-Up at Monte Rosa Therapeutics Sparks Investor Buzz

TIPRANKS
·
May 23

Monte Rosa director Anthony Manning disposes 10,000 shares worth $180,100

Reuters
·
May 23

Monte Rosa Therapeutics to Participate in Upcoming Investor Conferences

GlobeNewswire
·
May 20

Monte Rosa Therapeutics Is Maintained at Overweight by JP Morgan

Dow Jones
·
May 12

Analysts Offer Insights on Healthcare Companies: Foghorn Therapeutics (FHTX) and Monte Rosa Therapeutics (GLUE)

TIPRANKS
·
May 08

Monte Rosa Therapeutics reports Q1 revenue $4.21M, consensus $11.39M

TIPRANKS
·
May 08

Monte Rosa Therapeutics Inc reports results for the quarter ended March 31 - Earnings Summary

Reuters
·
May 07

Monte Rosa Therapeutics Q1 collaboration revenue drops 95%

Reuters
·
May 07

Monte Rosa publishes investor presentation on molecular glue degrader pipeline and Phase 2 plans

Reuters
·
May 07